Please assess the completion status of the following clinical trial:

Trial Title: Brentuximab for Newly Diagnosed Hodgkin Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Normal Serum creatinine based on age or creatinine clearance \>60 ml/min/1.73 m2 or an equivalent radioisotope glomerular filtration rate (GFR) as determined by the institutional normal range.~* Direct bilirubin \< 1.5 upper limit of normal (ULN) for age, and SGOT (AST) or SGPT (ALT) \<3 x ULN~* Shortening fraction \>27% by echocardiogram, or~* Ejection fraction of \>50% by radionuclide angiogram or echocardiogram.~* For patients age 1-16 years, Lansky score of ≥60.~* For patients \> 16 years, Karnofsky score of ≥60.~* No prior Hodgkin lymphoma directed therapy is allowed except for emergent mediastinal irradiation (\<1000cGy) for superior vena cava (SVC) syndrome.~Exclusion Criteria:~* Females who are pregnant (positive HCG) or lactating.~* Karnofsky \<60% or Lansky \<60% if less than 16 years of age.~* Age ≤1 year or \>29.99 years of age.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 29 Years
- Healthy Volunteers: f

Study Arms:
- Low Risk (Type: EXPERIMENTAL): Low Risk Patients (Stage IA, IIA; no bulky disease or extension): 3 cycles of chemotherapy
- Intermediate Risk (Type: EXPERIMENTAL): Intermediate Risk Patients (Stage IA bulk/E, IB, IIA bulk/E, IIB, IIIA): 4 cycles of chemotherapy
- High Risk (Type: EXPERIMENTAL): High Risk Patients (Stage IIIA bulk/ E, IIIB, IVA/B): 6 cycles of chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).